Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Strategic Partnership Between Genedata And SCIEX Deepens And Accelerates Characterization Of Next Generation Biotherapeutics

The collaboration will drive the development of new software solutions for in-depth characterization of novel biotherapeutics during the drug development process.

SCIEX, a global leader in life science analytical technologies, and Genedata, leading provider of biopharma enterprise software solutions, have entered into a strategic partnership to develop new software solutions for the biopharmaceutical mass spectrometry market. The goal of this partnership is to jointly innovate new workflows that leverage the proven Genedata Expressionist enterprise software platform and the analytical power of new SCIEX hardware such as the ZenoTOF 7600 system. This smart integration of software and hardware will allow biopharma customers to characterize progressively more complex molecules with increased speed and confidence, ultimately allowing them to accelerate the development of life-changing drugs.

SysAdmin Appreciation Day: Top Industry Leaders Share their Insights on IT and Data Ops

Related Posts
1 of 20,027

“Genedata Expressionist has become the software solution of choice for the characterization and quality monitoring of innovative biotherapeutics and related applications such as host cell protein analysis at many of the world’s leading biopharma organizations,” stated Othmar Pfannes, Ph.D., CEO of Genedata. “While we remain fully committed to supporting all instrument vendors, partnering at a strategic level is a logical next step to deliver tomorrow’s technology sooner to our joint customers. This will ultimately accelerate discovery, development, and commercialization of novel biopharmaceuticals, while reducing costs by streamlining and automating complex analytical processes.”

Recommended AI News: NetFortris Taps Raquel Wiley As Vice President Of Marketing

“Our customers tell us that the future of biotherapeutics lies in the development of next-generation therapies such as mAb variants, including multi-specific antibodies,” said Mani Krishnan, Vice President, and General Manager, CE & Biopharma, at SCIEX. “However, they also tell us the complexity of these molecules presents a significant characterization challenge in both analytics and data processing. This strategic partnership with Genedata will enable the development of customized data processing workflows to address key customer challenges, so that therapies can progress through the development pipeline faster.”

Recommended AI News: Alteryx and PwC Expand Strategic Relationship Globally to Address Analytics Automation Demand

Comments are closed.